<code id='5C7F0213ED'></code><style id='5C7F0213ED'></style>
    • <acronym id='5C7F0213ED'></acronym>
      <center id='5C7F0213ED'><center id='5C7F0213ED'><tfoot id='5C7F0213ED'></tfoot></center><abbr id='5C7F0213ED'><dir id='5C7F0213ED'><tfoot id='5C7F0213ED'></tfoot><noframes id='5C7F0213ED'>

    • <optgroup id='5C7F0213ED'><strike id='5C7F0213ED'><sup id='5C7F0213ED'></sup></strike><code id='5C7F0213ED'></code></optgroup>
        1. <b id='5C7F0213ED'><label id='5C7F0213ED'><select id='5C7F0213ED'><dt id='5C7F0213ED'><span id='5C7F0213ED'></span></dt></select></label></b><u id='5C7F0213ED'></u>
          <i id='5C7F0213ED'><strike id='5C7F0213ED'><tt id='5C7F0213ED'><pre id='5C7F0213ED'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:knowledge    Page View:9
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In